CANY
MYGN icon

Caxton Associates (New York)’s Myriad Genetics MYGN Stock Holding History

Caxton Associates (New York)’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,319
Closed -$533K – 605
2022
Q2 		$533K Buy
+29,319
New +$609K 0.05% 253
2020
Q3 		– Sell
-10,933
Closed -$124K – 446
2020
Q2 		$124K Buy
+10,933
New +$155K 0.01% 413

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Caxton Associates (New York)'s MYGN Position: Q3 2022 in Review

Caxton Associates (New York) sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 29,319 shares — an estimated $533K sold.

Caxton Associates (New York) first reported a position in MYGN in Q2 2020 and held it in 2 quarters. The position peaked at $533K in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

  • Caxton Associates (New York) reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 29,319 Myriad Genetics shares in Q3 2022, an estimated $533K.
  • Caxton Associates (New York) first reported a position in Myriad Genetics in Q2 2020 and held it in 2 quarters.
  • Caxton Associates (New York)'s Myriad Genetics position peaked at $533K in Q2 2022.
  • 191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Caxton Associates (New York)'s 13F filing for Q3 2022, filed 14 Nov 2022.